Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Q2 FY2020
As of Jun 30, 2020
Assets
Current Assets:
Cash and cash equivalents
Restricted cash
Short-term investments
Prepaid expenses and other current assets
Total current assets
Investments, non-current
Equipment, net
Other assets
Total assets
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable
Accrued expenses
Series B preferred stock tranche right liability
Total current liabilities
Total liabilities
Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount
Series A Redeemable Convertible Preferred Stock
Series B Redeemable Convertible Preferred Stock
Series C Redeemable Convertible Preferred Stock
Total redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount
Stockholders' Equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; no shares outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.0001 par value; 300,000,000 authorized as of March 31, 2022 and December 31, 2021; 21,630,627 and 21,630,572 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
Additional paid-in capital
Accumulated other comprehensive gain (loss)
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support